76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
D DarioHealth Corp
D
Closed
0.65
Overview
Share price change
24h
Min
0.63
Max
0.67
Income | 13M -9.8M |
|---|---|
Sales | 181K 7.6M |
EPS | -0.043 |
Profit margin | -128.763 |
Employees | 196 |
EBITDA | 369K -9.5M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +89.39% upside |
Next Earnings | 7 Aug 2025 |
|---|
Market Cap | 6.1M 30M |
|---|---|
Previous open | 0.65 |
Previous close | 0.65 |
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
DarioHealth Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
DarioHealth Corp Forecast
Price Target
By TipRanks
89.39% upside
12 Months Forecast
Average 1.25 USD 89.39%
High 1.5 USD
Low 1 USD
Based on 2 Wall Street analysts offering 12 month price targets forDarioHealth Corp - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About DarioHealth Corp
DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
